QuitinMyJob
4年前
RSCZF---. Big news $17.25 million LOI for Covid-19 test kits to the Chilean market! This one is going to explode one day soon imo.
https://www.otcmarkets.com/stock/RSCZF/news/story?e&id=1638731
ViraxClear Receives ISP Approval for ViraxClear Rapid Test Kit Distribution to Chile With Signed LOI for up to 3 million Test Kits
VANCOUVER, British Columbia, July 07, 2020 (GLOBE NEWSWIRE) -- Global Care Capital Inc. (CSE: HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that its portfolio company, ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd. (“SBD”) has received approval on July 3rd, 2020 from El Instituto de Salud Pública de Chile (“ISP”) for the distribution of COVID-19 Rapid Antibody Test Kits (“Test Kits”) supplied by its previously disclosed manufacturing partners, Innovita Biological Technology Co., Ltd and Vazyme Biotech Co., Ltd (“Innovita”, “Vazyme”), for the Chilean market. ViraxClear has signed a non-binding LOI with Biosonda Biotecnologia (“Biosonda”) for the distribution of up to 3 million Test Kits for the Chilean market, a contract valued at up to $17.25 million in gross revenue.
Figure 1
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f21c6f66-8b2f-4b6c-a13d-fd8e9822d37b
Distribution Contract for Test Kits in Chile
ViraxClear has received initial orders for trials and market testing of their Test Kits for the Chilean market and manufacturing is expected to commence over the next 60 days. The LOI provides for a 60-day exclusivity period during which ViraxClear and Biosonda intend to sign a definitive agreement with a total contract value of up to $17.25 million.
Biosonda is a biotechnology company founded in Chile in 1992 by leading scientists. It is currently one of the main distribution companies of products for scientific research and clinical diagnosis in Chile, with a recognizable corporate image in the national market. Biosonda works with some of the top global brands in the clinical and diagnostic industries and handle everything from marketing, import, logistics, research and development and sales.
The Biosonda commercial department is made up of a sales force, with a high degree of specialization and extensive experience in the market made up of experts in molecular biology and immunology. They offer a technical service laboratory for equipment maintenance, repair and training, a personalized after-sales service, and a commercial-logistics team that manages the tasks of quotation, import, logistics, inventory, orders and dispatch to provide an optimum service.
Alex Somjen, CEO of Global Care Capital Inc., stated, “This distribution deal represents the culmination of months of negotiating by ViraxClear with top distributors in key global regions. Biosonda is in a perfect position to roll out mass testing for the region with Chile already seeing 288,000 confirmed cases of COVID-19 and the population requiring Antibody Testing once the curve has flattened.”
ISP Approval
The Chilean government require medical testing devices to receive ISP Approval before they can be sold in Chile. Both Innovita and Vazyme, ViraxClear suppliers, are now on the list of ISP Approved factories, allowing ViraxClear tests to be imported and sold nationally.
Established in 2006, Innovita is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests. The CE and NMPA (formerly known as CFDA) approved Innovita serology tests have performed particularly well during preliminary clinical tests carried out by the COVID-19 Testing Project; a multidisciplinary team of researchers and physicians at UCSF, UC Berkeley, Chan Zuckerberg Biohub and Innovative Genetics Institute. According to their studies, Innovita tests scored a 96.3 % specificity (NPV); 83.3% Sensitivity (PPV) with an IN-HOUSE ELISA test (gold reference standard) giving 99.1 % specificity (NPV); 81.8 % Sensitivity (PPV): https://covidtestingproject.org/
Vazyme, which is a highly reputable producer of enzymes and antibodies with products covering clinical diagnosis, molecular diagnostics, high-throughput sequencing and life science research, as well as RNA sequencing, enabling customers and reagent manufacturers to get enzymes with higher resistance. Vazyme owns a dedicated 8000 m2 R&D site and have established the Biotechnology Industry Research Institute, which is comprised of a team of nearly 100 scientists.
The Test Kits are intended for the qualitative detection of IgG and IgM antibodies against 2019 Novel Coronavirus, produced by the immune system after virus infection. IgM is the earliest antibody that appears upon the first immune response, with detection indicating an early stage infection. IgG is produced later and lasts a long time in the body, indicating a prior infection. The combination of the two markers offers an insight into what stage the virus has reached.
About ViraxClear
ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.
http://www.viraxclear.com
info@viraxclear.com
About Global Care
Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.
http://www.globalcarecapital.com
GLOBAL CARE CAPITAL INC.:
Company Contact:
Alex Somjen, President & CEO
asomjen@globalcarecapital.com
Campeese
4年前
FDA COVID NEWS! $7 Mill DEAL.
June 25, 2020 (GLOBE NEWSWIRE) -- Global Care Capital Inc. (CSE: HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that its portfolio company, ViraxClear, through its joint venture, Shanghai Biotechnology Devices Ltd. has, further to the press release dated May 19th, 2020, received its approval certificate from the Philippines Food And Drug Administration (“PFDA”) for the distribution of COVID-19 Rapid Antibody Test Kits (“Test Kits”) for the Philippines market with a contract valued at up to $7.5 million in gross sales for the distribution of up to 1 million Test Kits for the Philippines.
https://www.globenewswire.com/NewsRoom/AttachmentNg/3348b7d1-3659-4a41-a664-b0b7e3942dc1
Distribution Contract for Test Kits in the Philippines
Following PFDA approval, Philippines medical device distribution company Novarad Asia Pacific Company (“Novarad”) has become ViraxClear’s exclusive distribution partner for the Philippines for ViraxClear Test Kits. The full contract value is worth up to $7.5 million, over a period of 1 year.
Alex Somjen, CEO of Global Care, stated “This distribution deal represents the first of many similar deals that ViraxClear is currently lining up with other strategic distribution partnerships it has been working on over the last few months. The Philippines is a major economy in South East Asia and we are excited to work with Novarad, who are very well positioned to market the ViraxClear products to its’ 100 million + population.”
PFDA Approval
The PFDA requires test kits to be on their approved list before being allowed through customs for sale in the country. ViraxClear tests have been approved in collaboration with Hangzhou Clongene Biotech Ltd., the ViraxClear manufacturing partner for the Philippines region.
Hangzhou Clongene Biotech Ltd. (“Clongene”) is a high-tech enterprise specialized in biological raw materials and in vitro diagnostic products. Founded in 2004, Clongene is equipped with state-of-the-art ISO 13485:2016 accredited- China GMP compliant R&D and manufacturing facilities covering 19,000 square meters in Hangzhou, China. Their products have obtained CE certificates, FSC certificates and US FDA 510(k) Clearances. Their product lines include Raw materials, Antibodies, Antigens, Enzymes, Immuno diagnosis, Fluorescence immunoassay (FIA) and Molecular diagnosis- PCR.
About ViraxClear
ViraxClear focuses on commercializing novel products that address significant healthcare needs with a specific target on the novel coronavirus (COVID-19). The company’s main focus is marketing its ViraxClear Rapid IgM-IgG Combined Antibody Test. The ViraxClear Rapid IgM-IgG Combined Antibody Test for COVID-19 is a lateral flow immunoassay used to qualitatively detect both early and late marker IgG/IgM antibodies.
http://www.viraxclear.com
info@viraxclear.com
About Global Care
Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.
GLOBAL CARE CAPITAL INC.:
Company Contact:
Alex Somjen, President & CEO
asomjen@globalcarecapital.com
Rob~daBanca
6年前
$RSCZF News Resinco Capital Partners Announces the Appointment of Sir Marc Feldmann to Advisory Board
https://finance.yahoo.com/news/resinco-capital-partners-announces-appointment-050000104.html
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2019) - Resinco Capital Partners Inc. (CSE: RIN) (OTC Pink: RSCZF) (FSE: L6V1) (the "Company" or "Resinco") is pleased to announce that the Company has appointed pioneer and trailblazer of modern immunology, Sir Marc Feldmann, to its Advisory Board after fully acquiring his company, ReFormation Pharmaceuticals Corp, a medical cannabis company developing innovative, first-in-class therapies to repair vital organs and stem cells by combining cannabinoids and an endogenous trigger of repair.
Sir Marc Feldmann, whose research breakthrough on inflammation led to the creation of some of the world's top-selling drugs like Humira and Remicade, is embracing medical marijuana, through co-founding ReFormation Pharmaceuticals with Professor Jagdeep Nanchahal. Specifically, ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body's own stem cells to accelerate repair and regeneration following acute or chronic injury.
"As medical marijuana regulations ease, Feldmann is paving the way for a new class of cannabis derived-drugs to treat pain and other conditions. His background and expertise will be valuable as we accelerate growth in the medical marijuana pharmaceutical space and capitalize on the industry's evolution," says Alex Somjen, President & CEO of Resinco.
"I am pleased to chair Resinco's Advisory Board and work with the team to advance the Second Generation of the Medical cannabis industry," said Sir Marc Feldmann, Chairman and Founder of ReFormation Pharmaceuticals. "Through rigorous clinical trials using FDA approved practices, we intend to accelerate ReFormation's development of cannabis treatments triggering stem cell repair, where the medical benefits are based on hard science and government regulation."
About Resinco Capital Partners
Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical cannabis pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.
Website: www.resincocp.com
About ReFormation Pharmaceuticals Corp
ReFormation Pharmaceuticals Corp is a medical cannabis pharmaceutical Company headquartered in Toronto, ON, with its Research and Development team at the University of Oxford. The Company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in-class therapeutic. The Company has identified a molecule that primes the body's own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. The Company's research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford.
Website: https://www.reformationpharma.com/
fred1963
6年前
Nice News Today!
https://www.newsfilecorp.com/release/42221/Resinco-Capital-Partners-Announces-Remaining-Acquisition-of-ReFormation-Pharmaceuticals-Corp
Resinco Capital Partners Announces Remaining Acquisition of ReFormation Pharmaceuticals Corp
ReFormation Developing First-in-Class Therapeutic to Repair Vital Organs by Combining Cannabinoids and Re-engineering a Molecule, HMGB1
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2019) - Resinco Capital Partners Inc. (CSE: RIN) (OTC Pink: RSCZF) (FSE: L6V1) (the "Company" or "Resinco") is pleased to announce that the Company has entered into a definitive agreement to acquire the remaining 51% of ReFormation Pharmaceuticals Corp, a medical cannabis company developing innovative, first-in-class therapies to repair vital organs and stem cells by combining cannabinoids and an endogenous trigger of repair. Resinco previously acquired 49% of ReFormation's outstanding shares on October 23, 2018.
Specifically, ReFormation Pharmaceuticals has identified a molecule (HMGB1) that primes the body's own stem cells to accelerate repair and regeneration following acute or chronic injury. Through the combination of this molecule and synthetic non-psychoactive cannabinoids they are developing a first-in-class therapy. ReFormation Pharmaceuticals is led by world-class scientist, Founder, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford.
“Resinco is extremely pleased to finalize this further investment into ReFormation. ReFormation is a tremendously innovative company, with all the attributes to disrupt the medical marijuana pharmaceutical space,” says Alex Somjen, President & CEO of Resinco Capital Partners Inc. “The Global Stem Cells Market is estimated to grow to $9.03 Billion by 2023[1] and having a company that focuses on an innovative approach to repair vital organs will be a beneficial investment as we position ourselves as a global investment company with an emphasis in ‘Second generation’ medicinal marijuana companies.”
"This acquisition will provide ReFormation with additional resources to help solve major medical unmet needs," said Prof. Nanchahal, of ReFormation. "The repair of major tissues will be another benefit of properly researching and developing the medical activities of cannabis-based products."
Finder's fees will be payable in accordance with the policies of the Canadian Securities Exchange. Pursuant to the terms of the ReFormation Agreement, ReFormation will amalgamate with the Company's wholly owned subsidiary, 1189879 B.C. Ltd., in consideration for 29,000,000 common shares of the Company. Upon completion of the transaction, Resinco's investment in ReFormation will be held through a wholly-owned subsidiary of the Company.
About Resinco Capital Partners
Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical cannabis pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.
Website www.resincocp.com
About ReFormation Pharmaceuticals Corp
ReFormation Pharmaceuticals Corp is a medical cannabis pharmaceutical Company headquartered in Toronto, ON, with its Research and Development team at the University of Oxford. The Company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in-class therapeutic. The Company has identified a molecule that primes the body's own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. The Company's research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and Chief Science Officer, Professor Jagdeep Nanchahal, of the University of Oxford.
Website: https://www.reformationpharma.com/
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com
RESINCO CAPITAL PARTNERS INC.:
Company Contact
Mr. Alexander Somjen, CEO
647-362-8998
Media Contact
Tim Gray, Account Director
KCSA Strategic Communications
Phone: 212.682.6300
Email: Resinco@KCSA.com
Pennybuster
6年前
Resinco Capital acquires B.C. firm Vancity Green List
2018-12-31 16:43 ET - News Release
Mr. Alexander Somjen reports
RESINCO CAPITAL PARTNERS ANNOUNCES STRATEGIC INVESTMENT WITH ACQUISITION OF VANCITY GREEN LIST INC.
Resinco Capital Partners Inc. has acquired the outstanding shares of Vancity Green List Inc., a private company based out of British Columbia.
The company entered into a definitive agreement with Vancity Green List and acquired 100 per cent of the issued and outstanding shares of Vancity Green List, by way of a three-cornered amalgamation, in consideration of the issuance of 15 million common shares of Resinco Capital Partners. Pursuant to the terms of the Vancity Green List agreement, Vancity Green List will now operate as a wholly owned subsidiary of Resinco Capital Partners.
Finders' fees will be payable on this transaction, in accordance with the policies of the Canadian Securities Exchange.
About Vancity Green List Inc.
Vancity Green List is a leading website application that connects personal-use cannabis growers and local dispensaries. With the legalization of cannabis products, personal-use cannabis growers will have the opportunity to have four plants within their household. With the yield that comes from these cannabis plants, there will be a surplus that can be commercialized.
Currently, there is a market shortage of cannabis products because of the recent government legalization and the lack of facilities to fill market demand. The national shortage is very real. More countries are legalizing cannabis, such as Croatia, Germany, Austria and New Zealand, and they are purchasing cannabis products from Canada, creating a shortage for the local market.
Vancity Green List has created a local database for personal-use growers and local dispensaries. Everyday personal-use growers will be able to upload their cannabis products for sale; the local dispensaries can then log in and search through the hundreds of personal-use growers and the products that they want to sell. Vancity Green List will be the leading business system that will connect personal-use growers and local dispensaries, while helping to eliminate the national shortage for cannabis products throughout Canada.
Alexander Somjen, president and chief executive officer of Resinco Capital Partners, commented: "Vancity's unique business model meets Resinco's investment mandate in search of new investment opportunities in the growing cannabis sector. These types of investments will continue to diversify and strengthen our existing portfolio."
Financing
Further to Resinco Capital Partners' news release dated Nov. 26, 2018, the company has cancelled the private placement offering of up to 15 million subscription receipts at a price of 20 cents per subscription receipt. The decision was made due to unfavourable market conditions.
About Resinco Capital Partners Inc.
Resinco Capital Partners is a global investment company which specializes in providing early-stage financing to private and public companies, as well as medical marijuana pharmaceutical companies. Resinco Capital Partners engages in new, early-stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early-stage investment opportunities that adequately reflect the risk profile.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.
Pennybuster
6年前
In October 2018, Resinco Capital acquired 49% of UK based pharma company ReFormation Pharmaceuticals in an all stock deal with the option to exercise future warrants. Rescino is a global investment company looking to expand into the cannabis/pharma sector.
The growth of the marijuana industry has been very rapid in the last two years. Since 2016, marijuana has been legalized in over 29 states. Support for marijuana legislation in the U.S. is also at its highest ever according to the latest Gallup poll.
Tilray, a Canadian pharmaceutical and cannabis company, made its debut on the NASDAQ this summer and soared from around $20 to as high as $300. Medical marijuana company Canopy Growth went from under $25 in August to over $52 in September, more than doubling.
Traders were celebrating the fact that the maker of Corona beer decided to invest a whopping $4 billion into the company. If that isn't confidence in the future of the marijuana industry, then what is?
Pot stocks may have experienced a healthy pullback recently after Canada legalized recreational marijuana on October 17th, but the gains have still been incredible this year and what could still be expected may blow these gains out of the water. Grand View Research has predicted that the global legal marijuana market is expected to reach a staggering $146.4 billion by end of 2025.
Resinco Capital Partners Inc. (OTC: $RSCZF) (CSE: RIN), has been developing a new concept: that the body's own stem cells that induce repair of tissues can be made to function more efficiently. This is very exciting and is something that could really shake up the medical arena.
Over the years, research after research has shown that marijuana is beneficial in the treatment of many conditions which include cancer, multiple sclerosis, epilepsy, arthritis, anxiety, IBS, and PTSD.
Epidiolex, the very first FDA-approved cannabis-based drug just became available in the U.S. at the start of November. When it gained FDA approval this past summer, it was a validation that the world is now ready for cannabinoid medicine.
The world could be more than ready for what Resinco Capital Partners Inc. (OTC: RSCZF) (CSE: RIN), is bringing to the table...
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Renee
2年前
Mrogers23
2年前
stock1ace1
4年前
jpast198
5年前
Can'tSparTheGhost
6年前
stocktrademan
6年前
